Cited 13 times in
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강은석 | - |
dc.contributor.author | 이민영 | - |
dc.contributor.author | 이병완 | - |
dc.contributor.author | 이용호 | - |
dc.contributor.author | 이지연 | - |
dc.contributor.author | 조용인 | - |
dc.contributor.author | 차봉수 | - |
dc.date.accessioned | 2019-07-11T03:30:03Z | - |
dc.date.available | 2019-07-11T03:30:03Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 2233-6079 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/170002 | - |
dc.description.abstract | BACKGROUND: We investigated the predictive markers for the therapeutic efficacy and the best combination of sodium-glucose co-transporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and ipragliflozin) therapy in patients with type 2 diabetes mellitus (T2DM). METHODS: A total of 804 patients with T2DM who had taken SGLT2 inhibitor as monotherapy or an add-on therapy were analyzed. Multivariate regression analyses were performed to identify the predictors of SGLT2 inhibitor response including the classes of baseline anti-diabetic medications. RESULTS: After adjusting for age, sex, baseline body mass index (BMI), diabetes duration, duration of SGLT2 inhibitor use, initial glycosylated hemoglobin (HbA1c) level, estimated glomerular filtration rate (eGFR), and other anti-diabetic agent usage, multivariate analysis revealed that shorter diabetes duration, higher initial HbA1c and eGFR were associated with better glycemic response. However, baseline BMI was inversely correlated with glycemic status; lean subjects with well-controlled diabetes and obese subjects with inadequately controlled diabetes received more benefit from SGLT2 inhibitor treatment. In addition, dipeptidyl peptidase 4 (DPP4) inhibitor use was related to a greater reduction in HbA1c in patients with higher baseline HbA1c ≥7%. Sulfonylurea users experienced a larger change from baseline HbA1c but the significance was lost after adjustment for covariates and metformin and thiazolidinedione use did not affect the glycemic outcome. CONCLUSION: A better response to SGLT2 inhibitors is expected in Korean T2DM patients who have higher baseline HbA1c and eGFR with a shorter diabetes duration. Moreover, the add-on of an SGLT2 inhibitor to a DPP4 inhibitor is likely to show the greatest glycemic response. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Diabetes Association | - |
dc.relation.isPartOf | DIABETES & METABOLISM JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ji-Yeon Lee | - |
dc.contributor.googleauthor | Yongin Cho | - |
dc.contributor.googleauthor | Minyoung Lee | - |
dc.contributor.googleauthor | You Jin Kim | - |
dc.contributor.googleauthor | Yong-ho Lee | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.contributor.googleauthor | Bong-Soo Cha | - |
dc.contributor.googleauthor | Eun Seok Kang | - |
dc.identifier.doi | 10.4093/dmj.2018.0057 | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A05491 | - |
dc.contributor.localId | A02796 | - |
dc.contributor.localId | A02989 | - |
dc.contributor.localId | A03197 | - |
dc.contributor.localId | A03866 | - |
dc.contributor.localId | A03996 | - |
dc.relation.journalcode | J00720 | - |
dc.identifier.eissn | 2233-6087 | - |
dc.identifier.pmid | 30688052 | - |
dc.subject.keyword | Blood glucose | - |
dc.subject.keyword | Diabetes mellitus, type 2 | - |
dc.subject.keyword | Glycated hemoglobin A | - |
dc.subject.keyword | Sodium-glucose transporter 2 inhibitors | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | 강은석 | - |
dc.contributor.affiliatedAuthor | 이민영 | - |
dc.contributor.affiliatedAuthor | 이병완 | - |
dc.contributor.affiliatedAuthor | 이용호 | - |
dc.contributor.affiliatedAuthor | 이지연 | - |
dc.contributor.affiliatedAuthor | 조용인 | - |
dc.contributor.affiliatedAuthor | 차봉수 | - |
dc.citation.volume | 43 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 158 | - |
dc.citation.endPage | 173 | - |
dc.identifier.bibliographicCitation | DIABETES & METABOLISM JOURNAL, Vol.43(2) : 158-173, 2019 | - |
dc.identifier.rimsid | 62319 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.